<DOC>
	<DOCNO>NCT00150176</DOCNO>
	<brief_summary>Schizophrenia brain disease . The condition may associate acute psychotic episode long-term disability despite remission acute symptom . Current management schizophrenia focus treatment acute symptom well long-term treatment aim prevent relapse patient experience improvement acute symptom . Patients discontinue treatment high likelihood experience relapse within 1-2 year acute episode schizophrenia . Patients remain antipsychotic treatment low rate relapse milder course exacerbation relapse occurs.The symptom schizophrenia may due imbalance chemical brain , primarily dopamine serotonin , enable brain cell communicate . Asenapine may help correct imbalance dopamine serotonin . The purpose clinical trial evaluate efficacy asenapine prevent relapse/impending relapse ( hereafter refer 'relapse ' ) subject treat asenapine symptom schizophrenia 26 week . In addition , determine safety tolerability asenapine 1-year treatment .</brief_summary>
	<brief_title>To Determine Long Term Efficacy Safety Asenapine Schizophrenic Patient Population ( A7501012 ) ( COMPLETED ) ( P05770 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Key Have primary diagnosis schizophrenia History least 1 prior episode acute schizophrenia 3 year precede screen History schizophrenia require continuous antipsychotic treatment least 1 year precede screen Clinically stable time entry define least 4 week period stable symptom Key Have uncontrolled , unstable clinically significant medical condition History suicide attempt significant violence others past 2 year A substanceinduced psychotic disorder behavioral disturbance think due substance abuse Current substance abuse/dependence Concurrent psychiatric disorder schizophrenia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>